Related Experiment Videos
Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD
B L Handen1, H M Feldman, A Lurier
1University of Pittsburgh School of Medicine, USA.
Insights
Methylphenidate (MPH) effectively treats hyperactivity and inattention in preschool children with developmental disabilities and ADHD. However, this age group may be more prone to adverse side effects, especially at higher doses.
Area of Science:
- Pediatric Neurology
- Child Psychiatry
- Developmental Pediatrics
Background:
- Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder.
- Preschool-aged children with ADHD often present with significant behavioral challenges.
- Developmental disabilities can co-occur with ADHD, complicating diagnosis and treatment.
Purpose of the Study:
- To evaluate the safety and efficacy of methylphenidate (MPH) in preschool children with ADHD and developmental disabilities.
- To compare MPH response in this population to existing data on school-aged children.
- To identify potential adverse effects of MPH in young children.
Main Methods:
- Double-blind, placebo-controlled, crossover study design.
- Involved 11 preschool children (aged 4.0-5.11 years) with ADHD and developmental disabilities.
- Administered MPH at 0.3 and 0.6 mg/kg doses, with placebo, assessing behavioral checklists and clinic observations.
Main Results:
- MPH showed significant improvements in hyperactivity and inattention ratings.
- Eight out of eleven children responded to MPH treatment.
- Five children experienced adverse effects, including social withdrawal and irritability, particularly at the higher dose.
Conclusions:
- Preschool children with developmental disabilities and ADHD demonstrate similar MPH response rates to school-aged children.
- This pediatric population appears particularly vulnerable to adverse drug reactions.
- Careful monitoring for side effects is crucial when prescribing MPH to young children.
Objective:
This was a double-blind, placebo-controlled, crossover design study of the safety and efficacy of methylphenidate (MPH) in 11 preschool children (aged 4.0-5.11 years) with developmental disabilities and attention-deficit hyperactivity disorder (ADHD).
Method:
MPH doses of 0.3 and 0.6 mg/kg per dose and a placebo were given. Drug response was evaluated via teacher-completed behavior checklists and clinic-based observations of activity level, attention, and compliance to adult requests. A side effects checklist was also completed by teachers and parents.
Results:
Significant improvement on teacher ratings of hyperactivity and inattention as well as clinic-based observations of activity level and compliance were associated with MPH. Eight of 11 preschool children were medication responders (based on a minimum 40% decrease between placebo and one drug condition on either the teacher-rated Conners Hyperactivity Index or the Hyperactive-Distractible subscale of the Preschool Behavior Questionnaire). Five children exhibited significant adverse drug side effects such as severe social withdrawal, increased crying, and irritability, especially at the higher dose (0.6 mg/kg).
Conclusions:
Results suggest that preschool children with developmental disabilities and ADHD respond to MPH at rates similar to those of school-age children with mental retardation and ADHD. However, this population appears to be especially susceptible to adverse drug side effects.